LEVEMIR FLEXTOUCH

Clinical safety rating: caution

Comprehensive clinical and safety monograph for LEVEMIR FLEXTOUCH (LEVEMIR FLEXTOUCH).

How it works

Insulin analog that activates insulin receptors, promoting glucose uptake and inhibiting gluconeogenesis.

What the body does with it

Metabolism	Hepatic metabolism via non-cytochrome P450 pathways.
Excretion	Renal: approximately 50-70% of administered dose undergoes renal clearance as intact insulin; fecal: negligible (<10%). Insulin detemir is extensively metabolized in the liver (via dipeptidyl peptidase IV and other proteolytic enzymes) and the kidney, with metabolites excreted in urine.
Half-life	Terminal half-life: approximately 5-7 hours (subcutaneous injection). The prolonged half-life relative to regular human insulin is due to reversible albumin binding, providing a flat, prolonged pharmacokinetic profile. Clinically, this supports once- or twice-daily dosing.
Protein binding	>98% bound to albumin. The high-affinity binding to albumin mediates the prolonged residence time and reduced variability.
Volume of Distribution	Approximately 0.11 L/kg (range 0.07-0.16 L/kg). The small volume reflects extensive albumin binding, limiting distribution to the vascular and interstitial spaces.
Bioavailability	Subcutaneous: approximately 60-80% (mean ~64%). Absorption rate is slower and more predictable than regular human insulin due to the acylation and albumin binding.
Onset of Action	Subcutaneous: gradual onset approximately 3-4 hours after injection. No intravenous route is indicated.
Duration of Action	Subcutaneous: duration of action is up to 24 hours (dose-dependent). At lower doses (≤0.4 U/kg), duration is approximately 16-20 hours; at higher doses, up to 24 hours. Provides a relatively flat action profile suitable for basal insulin coverage.

Classification & Brands

Dosing & administration

Subcutaneous injection, once or twice daily; starting dose 0.2-0.3 units/kg/day, titrate to target glycemic control.

Dosage form	INJECTABLE
Renal impairment	No dose adjustment required for GFR >30 mL/min; monitor glucose closely in severe renal impairment (GFR <30 mL/min) due to increased risk of hypoglycemia; consider dose reduction.
Liver impairment	No specific Child-Pugh based dose adjustments; monitor glucose closely in hepatic impairment due to altered glucose metabolism; dose reduction may be needed.
Pediatric use	Approved for ages 6-17 years; starting dose 0.2-0.3 units/kg/day subcutaneously once or twice daily; titrate based on glycemic response.
Geriatric use	Start at lower end of dosing range (e.g., 0.2 units/kg/day) due to renal function decline and increased fall risk; titrate cautiously to avoid hypoglycemia.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for LEVEMIR FLEXTOUCH (LEVEMIR FLEXTOUCH).

Breastfeeding	Insulin detemir is a large protein that is minimally excreted into breast milk. The M/P ratio is unknown. It is unlikely to affect the nursing infant due to low oral bioavailability. Compatible with breastfeeding.
Teratogenic Risk	Insulin detemir does not cross the placenta in significant amounts. No increased risk of major birth defects or miscarriage has been observed in pregnant women with diabetes. However, poorly controlled diabetes increases fetal risk (e.g., congenital anomalies in first trimester, macrosomia, hypoglycemia, stillbirth in second/third trimester).

Warnings & precautions

■ FDA Black Box Warning

Not indicated for treatment of diabetic ketoacidosis.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypoglycemia","Hypersensitivity to insulin detemir or excipients"]

Clinical Precautions

Precautions	["Hypoglycemia","Hypersensitivity reactions","Medication errors with other insulins","Renal or hepatic impairment may require dose adjustment","Thiazolidinedione co-administration increases edema and heart failure risk"]
Food/Dietary	No specific food restrictions, but meal timing and carbohydrate intake should be consistent to manage blood glucose. Alcohol may increase risk of hypoglycemia; limit intake and monitor glucose.

Clinical Tips & Counseling

Clinical Pearls

Drug interactions

Loading safety data…

LEVEMIR FLEXTOUCH

Clinical safety rating: caution

Comprehensive clinical and safety monograph for LEVEMIR FLEXTOUCH (LEVEMIR FLEXTOUCH).

How it works

Insulin analog that activates insulin receptors, promoting glucose uptake and inhibiting gluconeogenesis.

What the body does with it

Metabolism	Hepatic metabolism via non-cytochrome P450 pathways.
Excretion	Renal: approximately 50-70% of administered dose undergoes renal clearance as intact insulin; fecal: negligible (<10%). Insulin detemir is extensively metabolized in the liver (via dipeptidyl peptidase IV and other proteolytic enzymes) and the kidney, with metabolites excreted in urine.
Half-life	Terminal half-life: approximately 5-7 hours (subcutaneous injection). The prolonged half-life relative to regular human insulin is due to reversible albumin binding, providing a flat, prolonged pharmacokinetic profile. Clinically, this supports once- or twice-daily dosing.
Protein binding	>98% bound to albumin. The high-affinity binding to albumin mediates the prolonged residence time and reduced variability.
Volume of Distribution	Approximately 0.11 L/kg (range 0.07-0.16 L/kg). The small volume reflects extensive albumin binding, limiting distribution to the vascular and interstitial spaces.
Bioavailability	Subcutaneous: approximately 60-80% (mean ~64%). Absorption rate is slower and more predictable than regular human insulin due to the acylation and albumin binding.
Onset of Action	Subcutaneous: gradual onset approximately 3-4 hours after injection. No intravenous route is indicated.
Duration of Action	Subcutaneous: duration of action is up to 24 hours (dose-dependent). At lower doses (≤0.4 U/kg), duration is approximately 16-20 hours; at higher doses, up to 24 hours. Provides a relatively flat action profile suitable for basal insulin coverage.

Classification & Brands

Dosing & administration

Subcutaneous injection, once or twice daily; starting dose 0.2-0.3 units/kg/day, titrate to target glycemic control.

Dosage form	INJECTABLE
Renal impairment	No dose adjustment required for GFR >30 mL/min; monitor glucose closely in severe renal impairment (GFR <30 mL/min) due to increased risk of hypoglycemia; consider dose reduction.
Liver impairment	No specific Child-Pugh based dose adjustments; monitor glucose closely in hepatic impairment due to altered glucose metabolism; dose reduction may be needed.
Pediatric use	Approved for ages 6-17 years; starting dose 0.2-0.3 units/kg/day subcutaneously once or twice daily; titrate based on glycemic response.
Geriatric use	Start at lower end of dosing range (e.g., 0.2 units/kg/day) due to renal function decline and increased fall risk; titrate cautiously to avoid hypoglycemia.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for LEVEMIR FLEXTOUCH (LEVEMIR FLEXTOUCH).

Breastfeeding	Insulin detemir is a large protein that is minimally excreted into breast milk. The M/P ratio is unknown. It is unlikely to affect the nursing infant due to low oral bioavailability. Compatible with breastfeeding.
Teratogenic Risk	Insulin detemir does not cross the placenta in significant amounts. No increased risk of major birth defects or miscarriage has been observed in pregnant women with diabetes. However, poorly controlled diabetes increases fetal risk (e.g., congenital anomalies in first trimester, macrosomia, hypoglycemia, stillbirth in second/third trimester).

Warnings & precautions

■ FDA Black Box Warning

Not indicated for treatment of diabetic ketoacidosis.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypoglycemia","Hypersensitivity to insulin detemir or excipients"]

Clinical Precautions

Precautions	["Hypoglycemia","Hypersensitivity reactions","Medication errors with other insulins","Renal or hepatic impairment may require dose adjustment","Thiazolidinedione co-administration increases edema and heart failure risk"]
Food/Dietary	No specific food restrictions, but meal timing and carbohydrate intake should be consistent to manage blood glucose. Alcohol may increase risk of hypoglycemia; limit intake and monitor glucose.

Clinical Tips & Counseling

Clinical Pearls

Drug interactions

Loading safety data…